Brokers Add To Their Ratings On Advanced Accelerator Applications SA (NASDAQ:AAAP)

Jeannie Matthews
October 31, 2017

The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. Analysts giving the company a rating of 3 would be indicating a Hold recommendation. Of all stocks tracked, Advanced Accelerator Applications had the 9th highest net out-flow for the day.

03/16/2016 - Advanced Accelerator Applications S.A. had its "neutral" rating reiterated by analysts at Citigroup. The company's commercial products include Gluscan /Gluscan 500/Barnascan (R), IASOflu (R), IASOdopa (R), IASOcholine (R), MIBITEC/Adamibi and Leukokit (R). Advanced Accelerator Applications headquartered in Saint Genis Pouilly, France.

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) reported its EPS in the last quarter as $-0.26/Share lagging the analyst estimate of $-0.23/Share by a difference of $-0.03. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications. This showed a surprise of -13% in the last quarter earnings. 2 brokers rating the stock a strong buy, 1 analyst rating the company a buy, 1 brokerage rating the stock a hold, 0 brokerages rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $34.51.

Hutchison picks out one positive from Newcastle display after Burnley loss
Asked if Dyche was the reason why Burnley are so hard to beat, Hendrick told Sky Sports Premier League: "Definitely". Speaking after the game, he said: "It was a game we were controlling and we knew that scoring one goal would win it.

India, Pak trade fire in Poonch, girl injured
Pakistan and India had declared ceasefire in 2003 along the LoC, however, both accuse each other of violating the ceasefire. He further said that the Indian Army always maintains impeccable standards of professionalism and does not target civilians.

Ex-Catalan president takes refuge in Belgium under threat of charges
The source confirmed that the regional legislative had accepted Madrid's order for it to dissolve. They then boarded a plane from marseille to Brussels, reveals the Spanish press.

By taking a look at the stock's current statistics it can gauged that the stock candle is BULLISH with HIGH volatility.

CEO Stefano Buono, Chief Executive Officer of AAA, commented, "we have long felt (Novartis) would be an ideal partner, not only to enhance the launch of lutetium Lu 177 dotatate* (Lutathera®) for neuroendocrine tumors (NETs), but especially to accelerate the advancement of our unique oncology theragnostic platform". Tightening the gaze, stock performance for the last 5 trading days is -0.88%. The stock's price is 80.44 and their relative strength index (RSI) stands at 71.33. Institutional investors and hedge funds own 37.53% of the company's stock.

As per the memorandum of understanding, which has been approved by AAA's Board of Directors, Novartis will make a cash offer of $41 per ordinary share of AAA and $82 per American Depositary Share, subject to certain conditions, valuing the equity at $3.9 billion. AAAP has recorded a 50-day average of $0.00 and a two hundred day average of $0.00. As of today, the company has a SMA200 (200-day simple moving average) of 84.17 Percent. Analysts are projecting that the stock will reach $4.41 on a short term (1 year) basis. The return on invested capital is at -6.3%, which is good, compared to its peers. At the time of writing, the First Call consensus price target for the company is $57.02.

Other reports by

Discuss This Article